The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

Prostate

Volumn 60, Issue 4, 2004, Pages 332-337

  Ziada, Ali ^a   Barqawi, Albaha ^a   Glode, L Michael ^a   Varella Garcia, Marileila ^a   Crighton, Frances ^a   Majeski, Susan ^b   Rosenblum, Mark ^a   Kane, Madeleine ^c   Chen, Lin ^c   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Anschutz Cancer Pavilion   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; HER 2 receptor; Prostate; Trastuzumab

Indexed keywords

CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANOREXIA; ANTIBODY PRODUCTION; ARTICLE; ASCITES; ASTHENIA; BONE RADIOGRAPHY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRY SKIN; EDEMA; EVALUATION; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART PALPITATION; HOSPITALIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; RIGOR; SIDE EFFECT; SOFT TISSUE RADIOGRAPHY; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; VISUAL IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 3943104783     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20065     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5-26.
2. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000;88(Suppl 12):3009-3014.
3. Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001;28(1 Suppl 3):1-12.
4. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730):1132-1139.
5. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987;84(20):7159-7163.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-2648.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-792.
8. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(7):1800- 1808.
9. Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28(1 Suppl 3):38-44.
10. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18(21):3651-3664.
11. Mark HF, Feldman D, Das S, Sun CL, Samy M, Lathrop J. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genet Test 1999;3(2):237-242.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-712.
13. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94(4):980-986.
14. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59(4):803-806.
15. Oxley JD, Winkler MH, Gillatt DA, Peat DS. Her-2/neu oncogene amplification in clinically localized prostate cancer. J Clin Pathol 2002;55(2):118-120.
16. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92(23):1918-1925.
17. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999;59(19):4761-4764.
18. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-726.
19. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68(6):1140-1145.
20. Kita Y, Tseng J, Horan T, Wen J, Philo J, Chang D, Ratzkin B, Pacifici R, Brankow D, Hu S, Luo Y, Wen D, Arakawa T, Nicolson M. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem Biophys Res Commun 1996;226(1):59-69.
21. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41(3):697-706.
22. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988;2(4):387-394.
23. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9(3):1165-1172.
24. van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001;37(Suppl 1):11-17.
25. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol 2001;28(4 Suppl 15):71-76.